Skip to main content
Premium Trial:

Request an Annual Quote

Med BioGene Cuts Costs as Cash Dwindles

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Med BioGene today said that it has taken steps to reduce costs, including cutting staff, as its cash on hand shrinks.

The Vancouver, Canada-based molecular diagnostics developer had filed for a US initial public offering nearly a year ago but said today that it has been unsuccessful in completing that offering due to "unfavorable and deteriorating market conditions." Med BioGene said that there are a number of investment funds "considering an investment in the US IPO, or in a structured private financing, [but] there can be no assurance that a financing will be completed.

Med BioGene said that it currently has negative working capital and enough cash on hand to support current operations for approximately 60 to 90 days. However, it added, "there are no assurances that MBI will be able to avoid payment of certain outstanding payables and, as a result, such timeline may be significantly reduced."

The firm has not said how many employees have been terminated, but noted that it also has reduced the number of consultants to the company and is evaluating strategic alternatives, which may include a sales of company assets, collaborative agreements, a merger of sale of the company, or a winding down of the firm.

MBI also said it has reduced its board of directors from eight members to four. The directors continuing with the firm are Erinn Broshko, Heiner Dreismann, Dennis Grimaud, and Kevin Rooney. The others, Bruce Cousins, Hector MacKay-Dunn, Michael Hayden, and John Rayson, have resigned as directors.

MBI had planned to launch in the US this year its LungExpress Dx test, a 15-gene signature panel for identifying those patients with early-stage non-small-cell lung cancer who, following surgical removal of their tumor, are at a higher and lower risk of mortality.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.